ATLAS ACS2-TIMI 51

ATLAS ACS 2-TIMI 51 was a phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating an oral, direct factor Xa inhibitor (rivaroxaban) in subjects following an acute coronary syndrome. Subjects received low-dose aspirin therapy (75 to 100 mg/day), and enrollment was stratified based upon the intent of the investigator to administer a thienopyridine [Stratum 1 (aspirin only) and Stratum 2 (aspirin plus a thienopyridine)]. Two different doses of rivaroxaban were tested: 2.5 mg twice a day and 5.0 mg twice a day.

MAIN RESULTS:
Rivaroxaban in patients with a recent acute coronary syndrome
ATLAS ACS2-TIMI 51

PRESENTATIONS

TIMI 51 Slides
Atlas ACS2-TIMI 51 Poster (Alkhalfan AHA 2019)

PUBLICATIONS

Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial)

The Association of White Blood Cell Count and Bleeding in Acute Coronary Syndrome: An Insight Into the Atlas ACS-TIMI 51 Trial

D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy)

Evaluation of Cardiac Events in ATLAS ACS 2-TIMI 51

The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial

Rivaroxaban and Post-Stroke Neurological Outcomes in Patients With Acute Coronary Syndrome

Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial

The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 – TIMI 51 trial

The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes

Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2-TIMI 51)

Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51

Rivaroxaban in Patients Stabilized after a ST-Elevation Myocardial Infarction: Results from the ATLAS ACS 2-TIMI 51 Trial

Rivaroxaban in the Setting of Continued Dual Antiplatelet Therapy: Findings from the ATLAS ACS 2 – TIMI 51 Trial

Rivaroxaban Reduces Spontaneous and Large Myocardial Infarctions: findings from the ATLAS ACS 2 – TIMI 51 Trial

A Net Clinical Outcome Analysis Comparing Fatal or Irreversible Ischemic and Bleeding Events in ATLAS ACS 2 – TIMI 51

Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close